This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

SciClone Pharmaceuticals (Holdings) Yönetim

Yönetim kriter kontrolleri 2/4

SciClone Pharmaceuticals (Holdings) CEO'su Hong Zhao, Jun2020 tarihinde atandı, in görev süresi 4.08 yıldır. in toplam yıllık tazminatı CN¥ 25.33M olup, şirket hissesi ve opsiyonları dahil olmak üzere 32.6% maaş ve 67.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.18% ine doğrudan sahiptir ve bu hisseler HK$ 20.59M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.1 yıl ve 3.4 yıldır.

Anahtar bilgiler

Hong Zhao

İcra Kurulu Başkanı

CN¥25.3m

Toplam tazminat

CEO maaş yüzdesi	32.6%
CEO görev süresi	4.1yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	2.1yrs
Yönetim Kurulu ortalama görev süresi	3.4yrs

Son yönetim güncellemeleri

Recent updates

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Apr 02

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Dec 14

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Jun 19

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

May 31

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Feb 17

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Dec 02

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Oct 04

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Jul 27

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Jun 02

CEO Tazminat Analizi

Hong Zhao'un ücretlendirmesi SciClone Pharmaceuticals (Holdings)'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2023	CN¥25m	CN¥8m	CN¥1b
Sep 30 2023	n/a	n/a	CN¥1b
Jun 30 2023	n/a	n/a	CN¥953m
Mar 31 2023	n/a	n/a	CN¥904m
Dec 31 2022	CN¥17m	CN¥8m	CN¥855m
Sep 30 2022	n/a	n/a	CN¥844m
Jun 30 2022	n/a	n/a	CN¥833m
Mar 31 2022	n/a	n/a	CN¥878m
Dec 31 2021	CN¥26m	CN¥7m	CN¥923m
Sep 30 2021	n/a	n/a	CN¥837m
Jun 30 2021	n/a	n/a	CN¥779m
Mar 31 2021	n/a	n/a	CN¥766m
Dec 31 2020	CN¥29m	CN¥7m	CN¥754m
Sep 30 2020	n/a	n/a	CN¥817m
Dec 31 2019	CN¥15m	CN¥6m	CN¥615m

Tazminat ve Piyasa: Hong 'nin toplam tazminatı ($USD 3.48M ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 510.44K ).

Tazminat ve Kazançlar: Hong 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Hong Zhao (61 yo)

4.1yrs

Görev süresi

CN¥25,334,000

Tazminat

Mr. Hong Zhao has been President and Chief Executive Officer at SciClone Pharmaceuticals (Holdings) Limited since June 24, 2020 and also serves as its Executive Director since June 24, 2020. Mr. Zhao serve...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hong Zhao	CEO, President & Executive Director	4.1yrs	CN¥25.33m	0.18% HK$ 20.6m
Rongrong Pan	Company Secretary	less than a year	CN¥6.92m	0.026% HK$ 3.0m
Chihwen Shao	VP & Head of Technical Operations and Pharmacovigilance	2.5yrs	Veri yok	Veri yok
Min Jia	VP & Head of Immunization Business Unit	no data	Veri yok	Veri yok
Mingxiang Wu	VP and Head of Market Access & Commercial Operation (MACO) Department	no data	Veri yok	Veri yok
Lianzong Wu	VP and Head of Registration & Pharmaceutical Affairs Department	no data	Veri yok	Veri yok
Li Mao	VP, GM of Research and Development & Chief Medical Officer	2.1yrs	Veri yok	Veri yok
Min Wu	VP & Chief Business Development Officer	less than a year	Veri yok	Veri yok

2.1yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 6600 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hong Zhao	CEO, President & Executive Director	4.1yrs	CN¥25.33m	0.18% HK$ 20.6m
Rongrong Pan	Company Secretary	1.2yrs	CN¥6.92m	0.026% HK$ 3.0m
Daniel Vasella	Non-Executive Director	3.9yrs	CN¥658.00k	Veri yok
Guoen Liu	Independent Non-Executive Director	3.4yrs	CN¥658.00k	Veri yok
Zhenfu Li	Non-Executive Chairman	4.1yrs	Veri yok	Veri yok
Wendy Hayes	Independent Non-Executive Director	3.4yrs	CN¥658.00k	Veri yok
Yi-Hsien Lin	Non-Executive Director	3.4yrs	Veri yok	Veri yok
Ping Chen	Independent Non-Executive Director	3.4yrs	CN¥658.00k	Veri yok
Yushao Gu	Independent Non-Executive Director	3.4yrs	CN¥658.00k	Veri yok

3.4yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 6600 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.4 yıldır).

This company listing is no longer active

SciClone Pharmaceuticals (Holdings) Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

SciClone Pharmaceuticals (Holdings) Limited Announces Retirement of Wang Haixia as Non-Executive Director

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited, Annual General Meeting, Jun 18, 2024

Sciclone Pharmaceuticals (Holdings) Limited Announces Executive Changes

Sciclone Pharmaceuticals (Holdings) Limited Announces Retirement of SHI Cen as Non-Executive Director

SciClone Pharmaceuticals (Holdings) Limited Appoints Lin Shirley Yi-Hsien as Member of the Audit Committee

Recent updates

SciClone Pharmaceuticals (Holdings) Limited Announces Retirement of Wang Haixia as Non-Executive Director

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited, Annual General Meeting, Jun 18, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Sciclone Pharmaceuticals (Holdings) Limited Announces Executive Changes

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 20%

SciClone Pharmaceuticals (Holdings) Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Investor sentiment improves as stock rises 15%

First half 2023 earnings released: EPS: CN¥1.00 (vs CN¥0.79 in 1H 2022)

SciClone Pharmaceuticals (Holdings) Limited to Report First Half, 2023 Results on Aug 17, 2023

SciClone Pharmaceuticals (Holdings) Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

SciClone Pharmaceuticals (Holdings) Limited Approves a Final Dividend for the Year Ended December 31, 2022

Upcoming dividend of HK$0.39 per share at 3.7% yield

Sciclone Pharmaceuticals (Holdings) Limited Announces Retirement of SHI Cen as Non-Executive Director

Full year 2022 earnings: EPS and revenues miss analyst expectations

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Investor sentiment improved over the past week

SciClone Pharmaceuticals (Holdings) Limited Announces Acceptance of Investigational New Drug Application for Vaborem by Center for Drug Evaluation of the China National Medical Products Administration

SciClone Pharmaceuticals (Holdings) Limited Appoints Lin Shirley Yi-Hsien as Member of the Audit Committee

Sciclone Pharmaceuticals (Holdings) Limited Announces Resignation of Ms. Li Quan as Non-Executive Director and A Member of the Audit Committee of the Board

SciClone Pharmaceuticals (Holdings) Limited Announces NMPA Approval of Biologics License Application of Danyelza (Naxitamab) for Patients with Relapsed or Refractory High-Risk Neuroblastoma in China

Investor sentiment improved over the past week

Insider recently sold HK$218m worth of stock

Less than half of directors are independent

Insider recently sold HK$62m worth of stock

EpicentRx Announces Start of Dosing in China for Global Phase 3 Clinical Trial REPLATINUM (NCT05566041) with Partner SciClone Pharmaceuticals

SciClone Pharmaceuticals (Holdings) Limited Announces First Patient Has Been Dosed in China in RRx-001 Phase III Clinical Trial for the Third Line and Beyond Small Cell Lung Cancer

First half 2022 earnings released: EPS: CN¥0.79 (vs CN¥0.98 in 1H 2021)

SciClone Pharmaceuticals (Holdings) Limited to Report Q2, 2022 Results on Aug 18, 2022

SciClone Pharmaceuticals (Holdings) Limited Announces NMPA Approval of IND of Danyelza (Naxitamab) and GM-CSF in Combination with Irinotecan and Temozolomide in Patients with High-Risk Neuroblastoma with Primary Refractory Disease or in First Relapse

SciClone Pharmaceuticals (Holdings) Limited Appoints MAO Li as Chief Medical Officer

Sciclone Pharmaceuticals (Holdings) Limited Approves Final Dividend for the Year Ended December 31, 2021

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2021 Results on Mar 24, 2022

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Investor sentiment improved over the past week

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Investor sentiment deteriorated over the past week

Non-Executive Director Xiaozhuo Wang has left the company

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Full year 2020 earnings released: EPS CN¥1.38 (vs CN¥1.13 in FY 2019)

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

SciClone Pharmaceuticals (Holdings) Limited has completed an IPO in the amount of HKD 2.180509 billion.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş